Evaluate the therapeutic effects of Sevelamer to reduce blood sugar levels, HbA1c, blood lipids and hs-CRP in patients with diabetic nephropathy

Evaluate the therapeutic effects Sevelamer to reduce blood sugar levels, HbA1c, blood lipids and hs-CRP in patients with diabetic nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016100423559N5

Enrollment

Registered

2016-11-06

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Diabetic nephropathy

Interventions

Treatment intentervention with sevelamer (Genian farmed Co) 800 mg two times in day for 3 months.

Treatment - Drugs

Treatment intentervention with sevelamer (Genian farmed Co) 800 mg two times in day for 3 months

Eligibility

Sex/Gender

All

Age

45 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Treated patients due to diabetic nephropathy with (6.5% 45 years Exclusion criteria: Use of chemotherapy medications, presence of associated malignancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid profile. Timepoint: At the beginning of study and 1, 2 and 3 months after intervention. Method of measurement: Lab.;Cell blood count. Timepoint: At the beginning of study and 1, 2 and 3 months after intervention. Method of measurement: Lab.	—

Secondary

Measure	Time frame
HbA1c serum level. Timepoint: At the beginning of study and 1, 2 and 3 months after intervention. Method of measurement: Lab.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hossein Fekri

Ardabil University of Medical Sciences

shamim.a1364@yahoo.com+98 45 3371 5846

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026